GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers, announced on September 10, 2026, that it has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026. The determination relates to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and the request has stayed any suspension or delisting action, allowing GeoVax’s common stock to continue trading on The Nasdaq Capital Market under the symbol “GOVX” at least through the hearing and any extension period granted by the Panel.
At the hearing, GeoVax intends to present its plan to regain and maintain compliance with Nasdaq listing standards. Chairman and CEO David Dodd commented, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution.” He added that the company continues to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen manufacturing and global preparedness capabilities, and engage potential strategic, funding, and development partners.
The Nasdaq listing issue is significant for investors and the biotechnology sector because a delisting could reduce liquidity and access to capital for GeoVax, which relies on financing to fund its costly clinical trials. However, the stay provides temporary relief and allows the company to focus on its core programs. GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address the need for expanded orthopoxvirus vaccine supply and biodefense preparedness.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
Dodd emphasized, “Our focus remains on building long-term value from GeoVax’s vaccine and immuno-oncology programs while addressing the Company’s near-term corporate and financing priorities. We believe the progress across our programs, together with the growing emphasis on vaccine supply resilience, biodefense preparedness and expanded global access, provides a strong foundation for our continued efforts.”
The outcome of the Nasdaq hearing could impact GeoVax’s ability to raise capital and execute its strategic plans, making it a critical event for stakeholders. For the broader industry, the case underscores the challenges small-cap biotechs face in maintaining listing requirements while advancing high-risk, high-reward medical innovations. GeoVax’s pipeline, if successful, could contribute to global health security by providing new tools against mpox, smallpox, and cancer. For more information, visit www.geovax.com.
